Climb Bio, Inc.
CLYMNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$67.9M | −$82.0M | −$40.3M | −$45.1M | −$35.7M | −$20.9M |
| Net income | −$59.9M | −$73.9M | −$35.1M | −$45.2M | −$47.5M | −$20.7M |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M | $24.6M |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M | $3.1M |
| Equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M | −$25.0M |
| EPS (diluted) | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-4.24 | — |
| Shares out. | 67.5M | 27.7M | 26.6M | 26.6M | 26.6M | 3.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −37.3%
- Return on assets
- −35.7%
- Return on capital (ROCE)
- −42.2%
- Liabilities / assets
- 4.3%
- Debt / equity
- 0.05×
- Book value / share
- $2.38
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 18.70safe
- Accruals / assets
- −3.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- EARLY_Phase 1Active Not Recruitingreadout ~2026-04A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
- Phase 1Recruitingreadout ~2026-07A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
- Phase 1Recruitingreadout ~2027-04A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- Phase 1/2Recruitingreadout ~2027-08A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
- Phase 1/2Not Yet Recruitingreadout ~2027-09A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- Phase 2Recruitingreadout ~2027-10A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ra Capital Management, L.P.Activist (13D)Apr 29, 2026
- Mpm Bioimpact LlcPassive (13G)Feb 17, 2026
- Ai Eti LlcActivist (13D)Oct 16, 2025
- Pontifax Management 4 G.P. (2015) Ltd.Passive (13G)Sep 18, 2025
- Bml Investment Partners, L.P.Passive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Thomas Stephen BasilDirector | Feb 25, 2026 | Sell | 33,687 | $7.00 |
| Thomas Stephen BasilDirector | Feb 12, 2026 | Sell | 90,000 | $5.23 |
| Ra Capital Management, L.P.Director | Jan 5, 2026 | Buy | 7,111 | $3.50 |
| Ra Capital Management, L.P.Director | Dec 11, 2025 | D | 20.4M | $0.00 |
| Thomas Stephen BasilDirector | Aug 7, 2025 | Grant | 100,375 | $0.00 |
| Brennan AoifeOfficer — President and CEO | Jun 27, 2025 | Option exercise | 68,750 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.1M | 2.1 | +17.7% |
| Apr 30, 2026 | 1.8M | 2.0 | +10.3% |
| Apr 15, 2026 | 1.6M | 3.0 | -9.3% |
| Mar 31, 2026 | 1.8M | 4.0 | -1.6% |
| Mar 13, 2026 | 1.8M | 3.2 | +2.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Regulation FD disclosureMay 5, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventApr 28, 2026
- Director / officer changeApr 3, 2026
- Results of operationsMar 5, 2026
- Regulation FD disclosure · Other material eventJan 8, 2026
- Other material eventDec 31, 2025
- Entered a material agreement · Unregistered equity saleDec 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.